

Justification

of the Resolution of the Federal Joint Committee (G-BA) on
the Amendment of the Pharmaceuticals Directive (AM-RL):
Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a SGB V
Autologous Anti-CD-19-transduced CD3+ Cells (relapsed or
refractory mantle cell lymphoma);
Restriction of the Authority to Supply Care

of 21 July 2022

Contents

1.	Legal basis	2
2.	Key points of the resolution	2
3.	Bureaucratic costs calculation	3
4.	Process sequence	3

1. Legal basis

According to Section 35a, paragraph 3b, sentence 2 SGB V, the Federal Joint Committee may decide for a medicinal product that is or will be the subject of a resolution according Section 35a, paragraph 3b, sentence 1 SGB V that the authority to supply insured individuals such a medicinal product at the expense of the statutory health insurance is restricted to those care providers who participate in the required routine practice data collection according to Section 35a, paragraph 3b SGB V (restriction of the care providers' authority to supply care). The resolution is to be published online and is part of the Pharmaceuticals Directive (AM-RL).

2. Key points of the resolution

In its session on 21 July 2022, the G-BA decided on the restriction of the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V for the use of autologous anti-CD-19-transduced CD3+ cells in relapsed or refractory mantle cell lymphoma. The active ingredient autologous anti-CD-19-transduced CD3+ cells in relapsed or refractory mantle cell lymphoma is the subject of a resolution on the requirement of routine practice data collection according to Section 35a, paragraph 3b, sentence 1 SGB V.

The restriction of the authority to supply care to those care providers who participate in the required routine practice data collection according to Section 35a, paragraph 3b SGB V serves to obtain complete and valid data from the care of insured persons with the medicinal product and to prevent only fragmentary data collection in order to obtain reliable, suitable data for the purposes of the benefit assessment.

The need for information for a benefit assessment of autologous anti-CD-19-transduced CD3+ cells has led to the question of a (long-term) additional benefit compared to the appropriate comparator therapy for the approved patient population. A search by IQWiG for ongoing and planned data collection for the active ingredient autologous anti-CD-19-transduced CD3+ cells as part of the concept development for routine practice data collection showed that the ongoing and planned studies, including the extension studies, are not suitable for addressing the existing gaps in the evidence. The observational and registry studies commissioned by the regulatory authorities relate exclusively to the selective collection of data on the active ingredient autologous anti-CD-19-transduced CD3+ cells and not to a comparator data collection. The completed pivotal ZUMA-2 study is not comparative in design and thus cannot remedy the lack of comparison with existing appropriate therapeutic alternatives. The question of routine practice data collection requires the collection of comparator data.

The expected eligible number of subjects who can be treated with autologous anti-CD-19-transduced CD3+ cells is low because relapsed or refractory mantle cell lymphoma is a rare haemato-oncological disease, treatment with autologous anti-CD-19-transduced CD3+ cells is not an option for all subjects with relapsed or refractory mantle cell lymphoma, and other treatment options are available in the present therapeutic indication.

In order to ensure a sufficient data stock for the routine practice data collection, it is necessary that the data collection is as complete as possible, at least from the care context of insured persons with autologous anti-CD-19-transduced CD3+ cells.

Care providers within the meaning of Chapter 5, Section 60 of the G-BA's Rules of Procedure (VerfO) are physicians participating in SHI-accredited medical care, medical care centres and facilities according to Section 95 SGB V, as well as hospitals approved for care provision according to Section 108 SGB V.

Participation in the required routine practice data collection is ensured by the proper (proven in writing) participation of the (approved) healthcare provider in the data collection for the required routine practice data collection on the basis of the confirmed study protocol of the pharmaceutical company. In this context, efforts must also be made to ensure that the data transmission is as complete as possible.

3. Bureaucratic costs calculation

The proposed resolution does not create any new or amended information obligations for care providers within the meaning of Annex II to Chapter 1 VerfO and, accordingly, no bureaucratic costs.

4. Process sequence

In order to hold consultations and prepare a recommendation for a resolution on the initiation of a written statement procedure for the restriction of the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V, the Subcommittee on Medicinal Products commissioned a working group (Section 35a) consisting of the members nominated by the leading organisations of the care providers, the members nominated by the SHI umbrella organisation, and the representative(s) of the patient organisations. Representatives of the IQWiG also participate in the sessions. The working group discussed the amendment of the AM-RL in its session on 4 May 2022.

The draft resolution to initiate a written statement procedure was discussed at the session of the Subcommittee on Medicinal Products on 10 May 2022 and the draft resolution was consented to.

At its session on 10 May 2022, the Subcommittee unanimously decided to initiate the written statement procedure according to Chapter 1, Section 10, Paragraph 1 of the G-BA's Rules of Procedure.

Statements were received during the written statement procedure. The oral hearing was held on 28 June 2022.

The evaluation of the written statements received and the oral hearing was discussed at the session of the subcommittee on 12 July 2022, and the proposed resolution was approved.

At its session on 21 July 2022, the plenum adopted a resolution to amend the Pharmaceuticals Directive.

Chronological course of consultation

Session	Date	Subject of consultation
Working group Section 35a	4 May 2022	Consultation on the amendment of the AM-RL
Subcommittee Medicinal products	10 May 2022	Discussion and consensus on the draft resolution Resolution to initiate the written statement procedure on the amendment of the AM-RL Scheduling the oral hearing
Working group Section 35a	22 June 2022	Consultation on the statements received
Subcommittee Medicinal products	28 June 2022	Conduct of the oral hearing
Working group Section 35a	5 July 2022	Consultation on the draft resolution and evaluation of the written statement procedure
Subcommittee Medicinal products	12 July 2022	Concluding discussion of the draft resolution
Plenum	21 July 2022	Adoption of the resolution on the amendment of Annex XII AM-RL

Berlin, 21 July 2022

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken